Research status and pharmaceutical care for coronavirus infection treatment with chloroquine

The "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 6)" issued by the National Health Commission and the State Administration of Traditional Chinese Medicine proposed for the first time that chloroquine phosphate can be tried in the treatment of novel coronavirus pneumonia (COVID-19). The mechanism of action of chloroquine in the treatment of viral infection includes inhibiting the virus through pH-dependent inhibition of replication processes such as virus penetration and uncoating; inhibiting the virus by interfering with the binding of viral mucin and angiotensin-converting enzyme 2; The expression of inflammatory cytokines such as tumor necrosis factor alpha and autophagy inhibit the inflammatory response. Most of the studies on chloroquine in the treatment of coronavirus infection are in vitro tests, and there are no clinical research results on the efficacy and safety of the drug for COVID-19. Chloroquine can cause adverse reactions in multiple systems or organs, including cardiovascular system, eye, skin, digestive system, neuropsychiatric system, endocrine system, blood system, and ear, etc., and it interacts with a variety of drugs. This article puts forward specific suggestions on the pharmaceutical care in the process of clinical medication.